These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 31479762)

  • 21. In vitro activity of imipenem-relebactam against various resistance phenotypes/genotypes of Enterobacterales and Pseudomonas aeruginosa isolated from patients across Canada as part of the CANWARD study, 2016-2019.
    Walkty A; Karlowsky JA; Baxter MR; Adam HJ; Golden A; Lagace-Wiens P; Zhanel GG;
    Diagn Microbiol Infect Dis; 2021 Sep; 101(1):115418. PubMed ID: 34102373
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Imipenem/cilastatin/relebactam: A new carbapenem β-lactamase inhibitor combination.
    Mansour H; Ouweini AEL; Chahine EB; Karaoui LR
    Am J Health Syst Pharm; 2021 Mar; 78(8):674-683. PubMed ID: 33580649
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro activity of imipenem/relebactam plus aztreonam against metallo-β-lactamase-producing, OprD-deficient Pseudomonas aeruginosa with varying levels of Pseudomonas-derived cephalosporinase production.
    O'Donnell JN; Putra V; Belfiore GM; Maring BL; Young K; Lodise TP
    Int J Antimicrob Agents; 2022 Jun; 59(6):106595. PubMed ID: 35483625
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacodynamics of imipenem in combination with β-lactamase inhibitor MK7655 in a murine thigh model.
    Mavridou E; Melchers RJ; van Mil AC; Mangin E; Motyl MR; Mouton JW
    Antimicrob Agents Chemother; 2015 Feb; 59(2):790-5. PubMed ID: 25403667
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro activity of imipenem/relebactam against Gram-negative ESKAPE pathogens isolated in 17 European countries: 2015 SMART surveillance programme.
    Karlowsky JA; Lob SH; Kazmierczak KM; Hawser SP; Magnet S; Young K; Motyl MR; Sahm DF
    J Antimicrob Chemother; 2018 Jul; 73(7):1872-1879. PubMed ID: 29659861
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacodynamic modeling of beta-lactam antibiotics for the empiric treatment of secondary peritonitis: a report from the OPTAMA program.
    Kotapati S; Kuti JL; Nicolau DP
    Surg Infect (Larchmt); 2005; 6(3):297-304. PubMed ID: 16201939
    [TBL] [Abstract][Full Text] [Related]  

  • 27.
    Powles MA; Galgoci A; Misura A; Colwell L; Dingley KH; Tang W; Wu J; Blizzard T; Motyl M; Young K
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29866878
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A model-based analysis of pharmacokinetic-pharmacodynamic (PK/PD) indices of avibactam against Pseudomonas aeruginosa.
    Sy SKB; Zhuang L; Xia H; Schuck VJ; Nichols WW; Derendorf H
    Clin Microbiol Infect; 2019 Jul; 25(7):904.e9-904.e16. PubMed ID: 30394361
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Pharmacokinetics and Pharmacodynamics of Imipenem-Cilastatin/Relebactam Combination Therapy.
    McCarthy MW
    Clin Pharmacokinet; 2020 May; 59(5):567-573. PubMed ID: 32009210
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A mathematical model-based analysis of the time-kill kinetics of ceftazidime/avibactam against Pseudomonas aeruginosa.
    Sy SKB; Zhuang L; Xia H; Beaudoin ME; Schuck VJ; Nichols WW; Derendorf H
    J Antimicrob Chemother; 2018 May; 73(5):1295-1304. PubMed ID: 29415212
    [TBL] [Abstract][Full Text] [Related]  

  • 31.
    Lob SH; Hackel MA; Kazmierczak KM; Young K; Motyl MR; Karlowsky JA; Sahm DF
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28320716
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimization of dose and dose regimen of biapenem based on pharmacokinetic and pharmacodynamic analysis.
    Takata T; Aizawa K; Shimizu A; Sakakibara S; Watabe H; Totsuka K
    J Infect Chemother; 2004 Apr; 10(2):76-85. PubMed ID: 15160299
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Determine Optimal Dosing of Ceftazidime-Avibactam for the Treatment of Acute Pulmonary Exacerbations in Patients with Cystic Fibrosis.
    Bensman TJ; Wang J; Jayne J; Fukushima L; Rao AP; D'Argenio DZ; Beringer PM
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28784670
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA Program.
    Ong CT; Kuti JL; Nicolau DP;
    Surg Infect (Larchmt); 2005; 6(4):419-26. PubMed ID: 16433606
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics/pharmacodynamics of a β-lactam and β-lactamase inhibitor combination: a novel approach for aztreonam/avibactam.
    Singh R; Kim A; Tanudra MA; Harris JJ; McLaughlin RE; Patey S; O'Donnell JP; Bradford PA; Eakin AE
    J Antimicrob Chemother; 2015 Sep; 70(9):2618-26. PubMed ID: 26024868
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetic-pharmacodynamic modeling and simulation for in vivo bactericidal effect in murine infection model.
    Katsube T; Yamano Y; Yano Y
    J Pharm Sci; 2008 Apr; 97(4):1606-14. PubMed ID: 17705288
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Population Pharmacokinetics and Dosing Optimization of Imipenem in Children with Hematological Malignancies.
    Dong L; Zhai XY; Yang YL; Wang L; Zhou Y; Shi HY; Tang BH; Wu YE; Yang F; Wen L; Kong HX; Zhi LJ; Jacqz-Aigrain E; Zhao W
    Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30962334
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relebactam Is a Potent Inhibitor of the KPC-2 β-Lactamase and Restores Imipenem Susceptibility in KPC-Producing Enterobacteriaceae.
    Papp-Wallace KM; Barnes MD; Alsop J; Taracila MA; Bethel CR; Becka SA; van Duin D; Kreiswirth BN; Kaye KS; Bonomo RA
    Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29610205
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro dynamics and mechanisms of resistance development to imipenem and imipenem/relebactam in Pseudomonas aeruginosa.
    Gomis-Font MA; Cabot G; Sánchez-Diener I; Fraile-Ribot PA; Juan C; Moya B; Zamorano L; Oliver A
    J Antimicrob Chemother; 2020 Sep; 75(9):2508-2515. PubMed ID: 32514525
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of Porins and bla
    Balabanian G; Rose M; Manning N; Landman D; Quale J
    Microb Drug Resist; 2018 Sep; 24(7):877-881. PubMed ID: 29782237
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.